Assessment of Informal Support Provided by Caregivers at Different Stages of Alzheimer's Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age60+
SponsorHospices Civils de Lyon

About this trial

In France, approximately 1,200,000 people aged 65 and over suffer from Alzheimer's disease or related disorders, of which Alzheimer's disease (AD) accounts for 70% of cases. This prevalence could double by 2050. The cognitive decline and progression to functional dependence that accompany AD are associated with a decline in quality of life, an increased risk of comorbidities, institutionalization, and mortality, as well as high care costs, placing a burden on the patient, their family and friends, and the healthcare system.

Informal care, i.e., care provided by a family member or caregiver, plays an important role in the overall management of major neurocognitive disorders (NCDs) associated with AD at home. In France, the annual cost of informal care for AD was estimated in 2008 at around €14 billion per year, or approximately 50% of the total annual cost of AD. The economic valuation of informal care serves to inform public decision-makers not only about the cost of this resource, but also about its usefulness. The issue of resource allocation (particularly the daily allowance for family caregivers - AJPA in French) at the societal level and the sharing of private (role of caregivers) and public (role of the state and local authorities) responsibilities leads us to question the determinants of this usefulness, particularly the clinical determinants in AD patients at different stages of the disease.

The main hypothesis is that informal care varies according to cognitive decline and loss of autonomy, independently or in interaction with the number and type of the patient's comorbidities, their behavioral disorders, and the caregiver's burden.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients from Charpennes Hospital included in the MEM-AURA cohort

Patients aged 60 years and older at inclusion

Patients with dementia due to clinically probable Alzheimer's disease, regardless of stage

Patients with a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion

Disqualifiers

- Patients or caregivers who have expressed their opposition to the study

Patients living in institutions or nursing homes

Patients protected by law (under legal protection, guardianship, or conservatorship)

Trial population

Elderly patients attending memory consultations at Charpennes Hospital (HCL) for cognitive complaints. Patients from Charpennes Hospital included in the MEM-AURA cohort, accompanied by a caregiver and aged 60 years and older at inclusion with NCD due to clinically probable Alzheimer's disease and a Mini-Mental State Evaluation (MMSE) score ≤ 26 at inclusion.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • " Ressources Utilisation in Dementia " (RUD) questionnaire.

    Other intervention

    Questionnaire on the use of services available to patients with dementia.

Treatment groups

312 Participants
are divided into 1 treatment group
Group A: Patients from Charpennes Hospital1 intervention

Trial outcomes

Primary outcomes

1

Informal care costs

Informal care will be collected according to the " Ressources Utilisation in Dementia " (RUD) questionnaire and valued in euros using replacement cost method.

Time frame
At inclusion or 15 days maximum after inclusion.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.